127 related articles for article (PubMed ID: 27824661)
1. Changes in health behavior 1 year after testing negative at a colorectal cancer screening: a randomized-controlled study.
Knudsen MD; Hjartåker A; Olsen MKE; Hoff G; de Lange T; Bernklev T; Berstad P
Eur J Cancer Prev; 2018 Jul; 27(4):316-322. PubMed ID: 27824661
[TBL] [Abstract][Full Text] [Related]
2. Psychological effects of colorectal cancer screening: Participants
Kirkøen B; Berstad P; Botteri E; Bernklev L; El-Safadi B; Hoff G; de Lange T; Bernklev T
World J Gastroenterol; 2016 Nov; 22(43):9631-9641. PubMed ID: 27920484
[TBL] [Abstract][Full Text] [Related]
3. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
4. Favorable lifestyle before diagnosis associated with lower risk of screen-detected advanced colorectal neoplasia.
Knudsen MD; de Lange T; Botteri E; Nguyen DH; Evensen H; Steen CB; Hoff G; Bernklev T; Hjartåker A; Berstad P
World J Gastroenterol; 2016 Jul; 22(27):6276-86. PubMed ID: 27468217
[TBL] [Abstract][Full Text] [Related]
5. Lifestyle predictors for non-participation and outcome in the second round of faecal immunochemical test in colorectal cancer screening.
Knudsen MD; Berstad P; Hjartåker A; Gulichsen EH; Hoff G; de Lange T; Bernklev T; Botteri E
Br J Cancer; 2017 Aug; 117(4):461-469. PubMed ID: 28704841
[TBL] [Abstract][Full Text] [Related]
6. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
[TBL] [Abstract][Full Text] [Related]
7. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.
Jensen CD; Corley DA; Quinn VP; Doubeni CA; Zauber AG; Lee JK; Zhao WK; Marks AR; Schottinger JE; Ghai NR; Lee AT; Contreras R; Klabunde CN; Quesenberry CP; Levin TR; Mysliwiec PA
Ann Intern Med; 2016 Apr; 164(7):456-63. PubMed ID: 26811150
[TBL] [Abstract][Full Text] [Related]
8. Do no harm: no psychological harm from colorectal cancer screening.
Kirkøen B; Berstad P; Botteri E; Åvitsland TL; Ossum AM; de Lange T; Hoff G; Bernklev T
Br J Cancer; 2016 Mar; 114(5):497-504. PubMed ID: 26867161
[TBL] [Abstract][Full Text] [Related]
9. What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy?
van Dam L; Korfage IJ; Kuipers EJ; Hol L; van Roon AH; Reijerink JC; van Ballegooijen M; van Leerdam ME
Eur J Cancer; 2013 Jul; 49(10):2321-30. PubMed ID: 23571149
[TBL] [Abstract][Full Text] [Related]
10. Long-term lifestyle changes after colorectal cancer screening: randomised controlled trial.
Berstad P; Løberg M; Larsen IK; Kalager M; Holme Ø; Botteri E; Bretthauer M; Hoff G
Gut; 2015 Aug; 64(8):1268-76. PubMed ID: 25183203
[TBL] [Abstract][Full Text] [Related]
11. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening.
Stegeman I; van Doorn SC; Mundt MW; Mallant-Hent RC; Bongers E; Elferink MA; Fockens P; Stroobants AK; Bossuyt PM; Dekker E
Cancer Epidemiol; 2015 Jun; 39(3):388-93. PubMed ID: 25910865
[TBL] [Abstract][Full Text] [Related]
12. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy.
Hol L; de Jonge V; van Leerdam ME; van Ballegooijen M; Looman CW; van Vuuren AJ; Reijerink JC; Habbema JD; Essink-Bot ML; Kuipers EJ
Eur J Cancer; 2010 Jul; 46(11):2059-66. PubMed ID: 20621736
[TBL] [Abstract][Full Text] [Related]
13. Acceptability of two colorectal cancer screening tests: pain as a key determinant in sigmoidoscopy.
Kirkøen B; Berstad P; Botteri E; Dalén E; Nilsen JA; Hoff G; de Lange T; Bernklev T
Endoscopy; 2017 Nov; 49(11):1075-1086. PubMed ID: 28938500
[No Abstract] [Full Text] [Related]
14. Attendance and yield over three rounds of population-based fecal immunochemical test screening.
Kapidzic A; Grobbee EJ; Hol L; van Roon AH; van Vuuren AJ; Spijker W; Izelaar K; van Ballegooijen M; Kuipers EJ; van Leerdam ME
Am J Gastroenterol; 2014 Aug; 109(8):1257-64. PubMed ID: 24980879
[TBL] [Abstract][Full Text] [Related]
15. Association between lifestyle and site-specific advanced colorectal lesions in screening with faecal immunochemical test and sigmoidoscopy.
Knudsen MD; Botteri E; Holme Ø; Hjartåker A; Song M; Thiis-Evensen E; Norvard ER; Schult AL; Randel KR; Hoff G; Berstad P
Dig Liver Dis; 2021 Mar; 53(3):353-359. PubMed ID: 33309513
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Colorectal Cancer Screening in Detecting Earlier-Stage Disease-A Nationwide Cohort Study in Denmark.
Larsen MB; Njor S; Ingeholm P; Andersen B
Gastroenterology; 2018 Jul; 155(1):99-106. PubMed ID: 29626451
[TBL] [Abstract][Full Text] [Related]
17. Lifestyle in population-based colorectal cancer screening over 2-year follow-up.
Helander S; Heinävaara S; Sarkeala T; Malila N
Eur J Public Health; 2018 Apr; 28(2):333-338. PubMed ID: 29020299
[TBL] [Abstract][Full Text] [Related]
18. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
19. Most participate in faecal immunochemical test-based colorectal cancer screening out of curiosity about their chances of developing cancer.
Denters MJ; Bossuyt PM; Deutekom M; Fockens P; Dekker E
Eur J Cancer Prev; 2015 May; 24(3):176-9. PubMed ID: 25734239
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
